Strategic Advisors LLC Sells 2,184 Shares of Gilead Sciences, Inc. (GILD)

Strategic Advisors LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,149 shares of the biopharmaceutical company’s stock after selling 2,184 shares during the quarter. Strategic Advisors LLC’s holdings in Gilead Sciences were worth $931,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Keel Point LLC boosted its position in shares of Gilead Sciences by 0.4% during the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 11 shares during the last quarter. West Oak Capital LLC boosted its position in shares of Gilead Sciences by 0.7% during the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 32 shares during the last quarter. First Heartland Consultants Inc. boosted its position in shares of Gilead Sciences by 0.4% during the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 39 shares during the last quarter. Arrow Financial Corp boosted its position in shares of Gilead Sciences by 0.3% during the 2nd quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock valued at $1,258,000 after acquiring an additional 45 shares during the last quarter. Finally, Westover Capital Advisors LLC boosted its position in shares of Gilead Sciences by 0.8% during the 1st quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock valued at $378,000 after acquiring an additional 46 shares during the last quarter. 76.30% of the stock is currently owned by institutional investors.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.44 on Monday. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The firm has a market capitalization of $94,626.13, a price-to-earnings ratio of 7.56, a P/E/G ratio of -1.21 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same period last year, the company earned $2.75 earnings per share. The company’s revenue for the quarter was down 13.2% on a year-over-year basis. analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.87%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.69%.

COPYRIGHT VIOLATION WARNING: This story was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://sportsperspectives.com/2017/11/20/strategic-advisors-llc-sells-2184-shares-of-gilead-sciences-inc-gild.html.

In related news, EVP Gregg H. Alton sold 50,000 shares of the stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the completion of the sale, the executive vice president now directly owns 113,237 shares of the company’s stock, valued at $8,945,723. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 666,819 shares of company stock valued at $52,303,086. Corporate insiders own 1.30% of the company’s stock.

Several research analysts have recently weighed in on GILD shares. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Thursday, August 31st. Deutsche Bank AG reissued a “buy” rating and set a $81.00 price target on shares of Gilead Sciences in a research report on Thursday, August 31st. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target on the stock in a research report on Friday, October 13th. Credit Suisse Group reissued an “outperform” rating and set a $85.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $84.87.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply